All In Biotech

Drug Trial Radar · NCT00443820

Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis

Last checked: Nov 19, 2026Latest source record: Apr 19, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 526 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

526

Actual

Start

Dec 2006

Primary completion

Jun 2008

Study completion Jun 2008

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 6, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus. This trial will study patients with mild to moderate toenail fungus disease of the big toenail and their responses to two treatment durations, 24 or 48 weeks.

Conditions

  • Onychomycosis

Interventions

  • terbinafineDrug

    Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks

  • PlaceboDrug

    Vehicle (placebo) once daily for 48 weeks

  • terbinafineDrug

    Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks

  • PlaceboDrug

    Vehicle (placebo) once daily for 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 WeeksTime frame: 52 weeks

Locations

23 sites in 3 countries. Site status is shown where the registry gives one.

  • Dr. Fred D. Youngswick

    Novato, California

  • Dr. Larry Doehring

    Northglenn, Colorado

  • Dr. Robert P. Dunne

    Melbourne, Florida

  • Dr. Mark Ling

    Newnan, Georgia

  • Dr. Jesse Plasencia

    Chicago, Illinois

  • Dr. John Mallory

    Overland Park, Kansas

  • Dr. Jeffrey Conrow

    Topeka, Kansas

  • Dr.Michael Kaye

    Covington, Louisiana

  • Dr. Max Weisfeld

    Baltimore, Maryland

  • Dr. Linda Stein-Gold

    Detroit, Michigan

  • Dr. Anna Glaser

    St Louis, Missouri

  • Dr. Richard Scher

    New York, New York

  • Dr. Joseph Jorrizo

    Winston-Salem, North Carolina

  • Dr. Anne Lucky

    Cincinnati, Ohio

  • Dr. Rich Phoebe

    Portland, Oregon

  • Dr. Patricia Westmorland

    Simpsonville, South Carolina

  • Dr. David Horowitz

    Nashville, Tennessee

  • Dr. Jay Lifshen

    Irving, Texas

  • Dr. Richard Pollak

    San Antonio, Texas

  • Dr. Patrick Agnew

    Virginia Beach, Virginia

  • Novartis Investigative Site

    Various Cities, France

  • Novartis

    Investigative Site, Germany

  • Novartis Investigative Site

    Various Cities, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.